News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Boehringer Ingelheim Corporation Exits Hepatitis C Field, Pulls Regulatory Filings For Faldaprevir


6/23/2014 7:40:32 AM

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

Germany's Boehringer Ingelheim is bowing out of the race to develop oral hepatitis C virus (HCV) therapies and has discontinued development of lead candidate faldepravir.

After a strategic review of its business, the company said it had elected to withdraw all regulatory filings for faldepravir - a protease inhibitor - because the "HCV treatment environment has significantly and rapidly evolved" in the last couple of years.

Help employers find you! Check out all the jobs and post your resume.

Read at News Release
Read at News Release


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES